BRIEF-Adcendo Aps Under Agreement, Co Will Sponsor Phase 1B Clinical Trial And Msd Will Provide Pembrolizumab

Merck & Co., Inc.

Merck & Co., Inc.

MRK

0.00

May 26 (Reuters) - Merck & Co Inc MRK.N:

  • ADCENDO APS: CLINICAL COLLABORATION SUPPLY AGREEMENT WITH MSD TO EVALUATE ADCE-T02 IN COMBINATION WITH KEYTRUDA

  • ADCENDO APS: UNDER AGREEMENT, CO WILL SPONSOR PHASE 1B CLINICAL TRIAL AND MSD WILL PROVIDE PEMBROLIZUMAB

  • ADCENDO APS: EACH COS RETAIN ALL COMMERCIAL RIGHTS TO THEIR RESPECTIVE COMPOUNDS, INCLUDING AS MONOTHERAPY OR AS COMBINATION THERAPIES

  • ADCENDO APS: ANTICIPATES DOSING FIRST PATIENT IN PHASE IB COMBINATION STUDY IN 2H 2026

Source text: ID:nCNW1MxFYa

Further company coverage: MRK.N


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.